Digital pathology
Paige
Digital pathology AI applications for cancer pathology, including Paige Prostate.
Last updated: June 4, 2026
Back to directoryPreciseDx PreciseBreast medical AI product profile
AI-powered breast cancer prognostic test that combines histology-derived features with clinical factors to help stratify recurrence risk for clinician review.
Digital pathology
Best fit
Breast cancer programs evaluating whether routine H&E pathology can add AI-supported recurrence-risk information alongside pathology, genomic assays, guidelines, and tumor-board review.
- Primary use case
- AI-enabled digital pathology prognostic testing for early-stage invasive breast cancer recurrence risk using H&E whole-slide images and clinical factors
- Audience
- Breast pathology teams, breast oncology programs, tumor boards, molecular diagnostics teams, and digital pathology governance committees
- Risk level
- High
- Pricing signal
- Commercial diagnostic pricing is not public; verify current ordering model, laboratory workflow, payer coverage, regional availability, and service terms.
- Official sources
- 5 official sources
Compare within workflow: Digital pathology · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
Product-specific review. These product-specific signals summarize what the cited sources imply before treating PreciseDx PreciseBreast as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat as high-risk oncology prognostic software or laboratory testing until the exact ordering pathway, laboratory status, FDA or local authorization, intended population, and report claims are confirmed. |
|---|---|
| Privacy | Review slide image transfer, clinicopathologic data fields, laboratory ordering, vendor privacy terms, business-associate or data-processing agreements, retention, support access, and whether de-identified data may be used for model improvement. |
| Evidence | Compare published analytical and external validation evidence with local breast cancer subtypes, specimen workflow, scanner diversity, follow-up horizon, recurrence endpoint, calibration, and incremental value over existing assays. |
| Workflow | Best governed as tumor-board decision support where pathologists and oncologists interpret the AI-derived risk score beside standard pathology, biomarkers, genomic tests, treatment guidelines, and patient-specific preferences. |
Where PreciseDx PreciseBreast fits
PreciseDx describes PreciseBreast as an AI digital pathology test that uses OncoIntelligence to combine AI-derived grade with clinical factors and generate a recurrence-risk score for early-stage breast cancer; peer-reviewed records describe analytical validation and external validation of the digital prognostic model, while the company privacy policy should be reviewed for data-handling terms before clinical adoption.
Not for: Autonomous treatment selection, replacing pathology or oncology judgment, use outside the validated breast cancer population, or deployment without local regulatory and laboratory workflow review.
What to verify before using PreciseDx PreciseBreast
- Whether PreciseBreast is available and authorized for the intended country, specimen type, breast cancer subtype, stage, and diagnostic or research workflow.
- How H&E slide images, clinicopathologic variables, reports, ordering data, retention, access controls, and any laboratory or platform partners handle PHI.
- Which validation cohorts match the local population, treatment context, recurrence endpoint, follow-up horizon, scanner workflow, and clinical decision being supported.
- How pathologists, oncologists, molecular tumor boards, and care teams review the score beside histologic grade, biomarkers, genomic tests, guidelines, and patient preferences.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- www.precisedx.ai / precisebreast
- www.precisedx.ai / publications
- pubmed.ncbi.nlm.nih.gov / 38114366
- pmc.ncbi.nlm.nih.gov / articles / PMC12369158
- www.precisedx.ai / privacy-policy
Related medical AI products
Digital pathology
PathAI
AI-enabled digital pathology platform with image management and algorithm access.
Digital pathology
Hologic Genius Digital Diagnostics
FDA-cleared digital cytology system combining volumetric imaging, Genius Cervical AI, image management, and cytologist or pathologist review.
Digital pathology
Ibex Medical Analytics
Clinical-grade AI pathology platform for cancer diagnostics and pathology workflow support.